# Safety and Efficacy of Activated Recombinant Human Factor VII in Cirrhotic Patients Undergoing Partial Hepatectomy

> **NCT01562821** · PHASE2 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 235 (actual)

## Conditions studied

- Acquired Bleeding Disorder
- Cirrhosis

## Interventions

- **DRUG:** activated recombinant human factor VII
- **DRUG:** activated recombinant human factor VII
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01562821
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-07
- **Primary completion:** 2002-12
- **Final completion:** 2002-12
- **Target enrollment:** 235 (ACTUAL)
- **Last updated:** 2017-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01562821

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01562821, "Safety and Efficacy of Activated Recombinant Human Factor VII in Cirrhotic Patients Undergoing Partial Hepatectomy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01562821. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*